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Summary The Confronting Chronic Obstructive Pulmonary Disease (COPD) Survey in
North America and Europe conducted during 1999–2000 aimed to identify interna-
tional differences in the clinical management of COPD and the patients’ perspectives
on their disease. Our aim was to validate the screening questionnaire used in this
study in a sample of patients presenting at a respiratory clinic.
Interviews were conducted at an outpatient clinic of the London Chest Hospital. Of
the 136 patients contacted, 25 refused or were not able to participate. Questionnaire
data were validated by comparison with medical records and spirometry on 104
patients.
Overall, the questionnaire correctly identified 86.5% of patients with a diagnosis of
COPD with a chance-corrected agreement (k¼ 0.66, SE 0.098), which indicates good
agreement between the questionnaire a and the medical records. The questionnaire
had a high sensitivity (92.0%) and specificity (72.4%) with respect to the diagnosis of
COPD.
The screening questionnaire used in The Confronting COPD Survey appears to be a
valid screening tool to differentiate COPD from other respiratory diseases.
& 2003 Elsevier Ltd. All rights reserved.
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Introduction
Chronic Obstructive Pulmonary Disease (COPD) is
defined by the Global Initiative for Chronic Ob-
structive Lung Diseases as ‘‘a disease state char-
acterised by airflow limitation that is not fully
reversible. The airflow is usually both progressive
and associated with an abnormal inflammatory
response of the lungs to noxious particles or
gases’’.1 High personal and society burden and
mortality accompany COPD. Projections for 2020
indicate an increase in COPD mortality from the 6th
position to the 3rd position, surpassed only by
cardiovascular and cerebrovascular disorders.2,3
An important contribution to the investigation of
COPD is provided by epidemiological studies con-
ducted in large population-based samples. In such
samples working definitions of COPD must be
implemented in order to discriminate with reason-
able accuracy between individuals at risk of COPD
and those who are not. These kind of screening
tools can make descriptive epidemiology studies
ARTICLE IN PRESS
*Corresponding author. Tel.: þ 44-20-89662930; fax: þ 44-20-
89662475.
E-mail address: Hana.X.Muellerova@gsk.com (H. M .ullerov!a).
0954-6111/$ - see front matter & 2003 Elsevier Ltd. All rights reserved.
doi:10.1016/j.rmed.2003.08.009
Respiratory Medicine (2004) 98, 78–83
more efficient, by restricting the number of
patients who require more detailed survey inter-
views.
Our validation study aimed to determine the
potential diagnostic value of a screening question-
naire used in The Confronting COPD International
Survey.5 The questionnaire presented here could
potentially be used to screen COPD out from the
general population by means of face-to-face, mail
or telephone surveys. Because COPD prevalence
rates in all ages vary from 0.5% to 2% by country, we
tested this screening questionnaire in a respiratory
clinic population with a high attendance of COPD
patients. As the sensitivity and specificity of a
diagnostic test are constant for the instrument, by
applying this questionnaire in an enriched COPD
sample with higher than usual prevalence of the
condition, we could determine its sensitivity and
specificity vs. the gold standard, in this case a
respiratory physician diagnosis of COPD.
Methods
Study population
Data were obtained from the 104 outpatients who
signed an informed consent and were older than 45
years, visiting for respiratory problems a specia-
lised respiratory outpatient clinic at the London
Chest Hospital during winter months’ 2001/2002.
Patients were unselected attendants of a 1-day/
week clinic. The study protocol was approved by
the East London & City Health Authority and all
study patients signed an informed consent in
concordance with the Helsinki declaration. Each
outpatient responded to a questionnaire adminis-
tered by a single person. Demographic and disease-
specific data were retrieved from medical records.
Questionnaire
The Personal Level Screener for COPD (see Appen-
dix) is a five-item questionnaire used in the
Confronting COPD Survey which aimed to identify
international differences in the current clinical
management of COPD, and the patients’ perspec-
tive on their disease.5
The development of the Confronting COPD
Survey questionnaires was based on pre-existing
questionnaires, mainly on the International Union
Against Tuberculosis and Lung Disease and the
European Community Respiratory Health Survey
questionnaires.6,7
Validation procedure
The aim of the study was to determine the
questionnaire validity as an instrument. Sensitivity,
specificity, positive and negative predictive values
and k coefficient of agreement were obtained.
The questionnaire case definition of COPD was:
(1) age 45 years or older, (2) at least 10 pack-years
of smoking, and (3) physician diagnosis of COPD,
emphysema or chronic bronchitis or symptoms
matching the definition of chronic bronchitis with
or without breathlessness (at least 3 months of
bronchitis or chronic coughing with phlegm/sputum
from the chest in the past 12 months for the last 2
years and/or repeatedly short of breath over the
past 12 months).
The medical records’ case definition of COPD
was: (1) age 45 years or older, (2) diagnosis of COPD
(emphysema, chronic bronchitis, COPD, chronic
obstructive airways disease, chronic obstructive
lung disease, or a1 antitrypsin deficiency), (3) ratio
of forced expiratory volume in 1 s/forced vital
capacity (FEV1/FVC)o70%, and (4) at least 10 pack-
years of smoking (except in cases diagnosed with a1
antitrypsin deficiency).
Smoking history was assessed using calculated
pack-years ([number of cigarettes per day/
20] the length of smoking in years). The sex–age
specific values of LFTwere calculated according to
the European Community for Coal&Steel guide-
lines.8
Statistical methods
Sample size was calculated prior to the study.
Based on the threshold level of sensitivity 70% and
specificity 90%, the sample size of 100 patients was
considered satisfactory to calculate k statistics of
0.6 (SE 0.099), which indicates good agreement of
an instrument.9,10
The EPIINFO 6.1 software was used for the
epidemiology-related calculations (sensitivity, spe-
cificity, and k). The relationships between respon-
ders vs. non-responders and COPD vs. non-COPD
patients were tested using the two-tailed student
t-test (a¼ 5%). The relationship between LFT and
age was measured using the Spearman correlation
coefficient.
Results
Of 136 patients contacted, 25 refused or were not
able to participate. In addition, seven patients
were excluded from the final analyses because of
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missing LFT data. Questionnaire data were com-
pared with medical records and spirometry based
on 104 patients.
The reasons for refusal can be split into two main
categories: time restrictions because of transport,
other investigations (n ¼ 14); and communication
barrier (physical/emotional distress, language bar-
rier, unwillingness to sign a consent form) (n ¼ 11).
The gender ratio, diagnosis and spirometry values
were comparable between patients who refused to
participate and the final sample (see Table 1). The
average age was significantly higher in those who
refused to participate compared to study partici-
pants (mean¼ 70.3 vs. 65.5 years; Pp0:05).
The average age of the final analysed sample
(n ¼ 104) was 65.5 years (SD 10.3), and the male to
female ratio was 49:51%. In the Table 2, the
distribution of demographic variables, main spiro-
metry and smoking history characteristics are
presented. There were 75 COPD cases and 29 non-
COPD patients in the final sample. Non-COPD
diagnosis included asthma (n ¼ 8), bronchiectasis
(n ¼ 8), asbestosis, fibrotic alveolitis, obstructive
sleep apnoe, pulmonary fibrosis, pulmonary hyper-
tension and sarcoidosis (all o3 patients each).
Age and gender distributions were comparable.
In all patients with a diagnosis of COPD at the
Chest Clinic, the diagnosis was confirmed by
spirometry values. The forced expiratory ratio
was substantially lower (Pp0:001) in COPD
cases (49.6%714.8%) than non-COPD cases
(71.8%711.9%). In the group of COPD patients,
the ratio of absolute to predicted values of FEV1
(49.6%714.8%) and FEV1/FVC (65.6%737.7%) point
out the significant reduction in the lung functions.
There were no statistically significant relationships
between age and LFT variables among COPD or the
other patients.
Almost 50% of non-COPD participants declared
themselves as non-smokers in contrast to only 5% of
COPD cases. The difference in smoking history
between the COPD and non-COPD cases is reflected
in the value of pack-years, which represented 36
pack-years in COPD cases vs. five pack-years in non-
COPD cases.
The measure of association between the ques-
tionnaire- and medical records-based diagnosis is
presented in Table 3. Overall, the questionnaire
correctly identified 88.5% patients with a diagnosis
of COPD, chance-corrected agreement k was 0.66
(SE 0.098). Sensitivity, the chance for a COPD
patient to be correctly recognised by the ques-
tionnaire, equaled to 92.0%. Specificity, the chance
for a non-COPD patient to be correctly recognised
as non-COPD case by the questionnaire, was 79.4%.
The positive and negative predictive values, pro-
portion of people with a positive test who have the
target disorder and proportion of people with a
negative test who do not have the target disorder,
was 92.0% and 79.3%, respectively.
Six COPD patients were not recognised by the
questionnaire, and hence, screened out (false
negative). In all cases, they were correctly sorted
by the disease-specific questions B and/or C (see
Appendix for the questionnaire), but they failed to
report a smoking history of more than 10 pack-years.
The significant differences, from the population of
COPD cases correctly detected, include gender ratio
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Table 1 Comparison of respondents and non-respondentsFdemographic and disease-related variables (one
patient might be diagnosed with more than one disease).
Variables Non-respondentsn Respondents
N 25 104
Age (mean, SE)w 70.379.7 65.5710.3
Gender (F/M) 12/13 53/51
Diagnosis
COPD (%) 64.7 71.1
Asthma (%) 5.9 8.6
Other (%) 29.4 36.5
FEV1 (mean, SE) (ml) 1025.07462.8 1228.47780.5
FEV1, % of predicted value (mean, SE) 52.5723.9 51.5721.2
FEV1/FVC (mean, SE) 58.7%717.9% 55.8%717.2%
FEV1/FVC, % of predicted value (mean, SE) 75.2718.3 73.1722.0
FEV1¼ forced expiratory volume in 1 s.
FEV1/FVC¼ forced expiratory ratio (forced expiratory volume in 1 s/forced vital capacity).
nAge, diagnosis and lung functions analyses based on available data from the population (n ¼ 23 for age, 20 for diagnosis, 19 for
FER).
wPo0:05:
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(more females among screened out) and FER value
(higher in screened outpatients). Those recognised
by the screening questionnaire but not by medical
records (false positive; n ¼ 6) did not differ signifi-
cantly from non-COPD patients. Of the eight asthma
patients in the sample, only one was misdiagnosed by
the questionnaire as a COPD patient.
Discussion
This study shows high specificity and sensitivity of
the validated questionnaire and the k coefficient
value of 0.66 indicates good agreement between
the Confronting COPD Survey screening question-
naire and medical records data.
This study does not describe the sensitivity and
specificity of the Personal Level Screening ques-
tionnaire in an unselected population. Instead, we
aimed to see if the Screener was able to distinguish
patients with COPD from patients with other
respiratory disorders. This is probably the most
important issue regarding the use of the instru-
ment, as few subjects without recognised respira-
tory disease are likely to be diagnosed with
COPDFespecially given the well-known level of
under-diagnosis of the disease.4
Even though COPD represents a common respira-
tory disorder, few standardised instruments have
been developed for screening of this disease. Most
instruments deal with respiratory symptoms and
health status assessment, or quality of life (St.
Georges Respiratory Questionnaire and the Chronic
Respiratory Disease Questionnaire).11,12 A search
for diagnostic screening scales revealed several
questionnaires related to specific respiratory dis-
orders.13–15 None of these questionnaires specifi-
cally targeted COPD with the aim to screen with
high-sensitivity potential COPD cases which can be
assessed later in detail.
The screening criteria as proposed here, are easy
to use, specifically constructed for COPD with low
demand on time and associated cost. The Personal
level Screener takes under 5min per individual to
be completed and might be useful to estimate
COPD prevalence in population-based settings. Very
high sensitivity (92.0%) and specificity (79.3%) and
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Table 3 The distribution of the questionnaire and
medical records determination of COPD vs. other
respiratory disease.
Questionnaire (test) Medical records Total (n)
COPD Other
COPD 69 (92%) 6 (21%) 77
Other 6 (8%) 23 (79%) 27
Total (n) 75 29 104
Table 2 Demographic and clinical characteristics of COPD and non-COPD participants (one patient might be
diagnosed with more than one disease).
Variables COPDn Non-COPDn
N 75 29
Age (mean, SE) 66.579.9 62.9711.3
Gender (F/M) 38/37 15/14
Diagnosis
COPD (%) 85.7 0
Asthma (%) 0 24.2
Other (%) 14.3 75.7
FEV1 (mean, SE) (ml)
w 1025.07462.8 1969.771004.2
FEV1, % of predicted value (mean, SE)
w 42.0718.1 75.9719.1
FEV1/FVC (mean, SE)
w 49.6%714.8% 71.8%711.9%
FEV1/FVC, % of predicted value (mean, SE)
w 65.6737.7 93.3715.6
Smoking statusz
Non-smoker (%) 5.3 48.3
Smoker (currentþ former) (%) 94.7 51.7
Smoking historyFnumber of pack-years (median) 36 5.0
FEV1¼ forced expiratory ratio in 1 s.
FEV1/FVC¼ forced expiratory ratio (forced expiratory ratio in 1 s/forced vital capacity).
nDistribution based on data from medical records.
wPo0:05:
zNot available from medical records, questionnaire (screener) data used.
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resulting k of 0.66 indicate high probability that a
COPD is identified by the validated questionnaire.
The relatively high refusal rate (25%) to partici-
pate can be explained by busy environment of the
specialised clinics, where the majority of patients
were referred from relatively distant areas. Time
restrictions represented the main reason for the
refusal. The second main reason for refusal,
physical and/or emotional distress, can be ex-
plained by the clinical picture of COPD as a severe,
quality-of-life reducing disorder.
Patients incorrectly classified by the question-
naire (false positives, false negatives) represented
11.5% of those interviewed. In the case of false
negatives (patients with COPD not recognised by a
questionnaire), the failure to report adequate
smoking history was the exclusive cause of mis-
diagnosis. The false positives (recognised as COPD
patients by the screener but not by medical
records) represented a mixed group of patients
with restrictive respiratory disorders with long-
term history of smoking and the symptom of
breathlessness.
In conclusion, the screening properties of the
Confronting COPD Survey Personal-level question-
naire confirmed its applicability as a screening tool
for surveys in database patient samples and clinical
practice.
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A. Are you over 45 years old? 
YES   (continue) 
NOT  (stop) 
Could you take a couple of minutes to read carefully this patient information leaflet and then 
sign this approval form? 
Could we begin now? ID#Patient: 
YES............1 (continue) 
NO .............2 (stop) 
B. Have you ever been diagnosed by a physician as having…….. 
       DIAGNOSED
NO YES 
1. Emphysema 2
2. Chronic bronchitis 2
3. Chronic Obstructive Pulmonary Disease (COPD),
Chronic obstructive airways disease (COAD), or
Chronic obstructive lung disease (COLD) 2
4. Alpha one antitrypsin deficiency 2
5. Asthma 2
1
1
1
1
1
C1. How many MONTHS in the past 12 months have you had bronchitis or chronic 
coughing with phlegm/sputum from the chest? 
_______ NUMBER OF MONTHS PER YEAR        IF LESS THAN THREE SKIP TO C3 
C2. For how many years have you had bronchitis or chronic coughing with  
phlegm/sputum from the chest for at least three months? 
_______ YEARS WITH REPEATED BRONCHITIS  IF LESS THAN TWO SKIP TO C3 
If three months or more in C1 and 2 years or more in C2, eligible as chronic bronchitis, skip to 
D. 
C3. Have you been repeatedly short of breath over the past 12 months? 
YES……………..1 ELIGIBLE FOR BREATHLESSNESS
NO……………….2 SCREEN OUT  
Appendix A. Personal level screener for COPD
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D. Have you ever smoked cigarettes on a daily basis? 
YES............1  
NO .............2 SCREEN OUT UNLESS DIAGNOSED as ALPHA ONE 
ANTITRYPSIN DEFICIENCY IN B4 
E. For how many years, in total, have you smoked cigarettes on a daily basis? 
_______ YEARS smoking        
F. How many cigarettes do you/ did you smoke per day, on average? _______________ 
[calculate # of pack years = (F/20) * E] 
IF FEWER THAN 10 THEN SCREEN OUT UNLESS DIAGNOSED as ALPHA ONE 
ANTITRYPSIN DEFICIENCY IN B4 
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